Talking Obesity with Daniel J. Drucker, Co-Inventor of Ozempic

Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the pioneers in advancing next-generation anti-obesity medications such as Ozempic in a new video series on obesity care. 
 
Drucker, who is a senior investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, and a university professor in the Department of Medicine at the University of Toronto’s Temerty Faculty of Medicine in Ontario, Canada, describes the discovery of glucagon-like peptides (GLP-1s) for treating obesity as a team effort and looks forward to future developments in obesity research. 
 
Watch the four-part video series:  

The Society’s ongoing “Talking Obesity” video series features our experts discussing the latest in obesity research and care. Topics include the discovery of the latest class of anti-obesity medications, how these medications have been lifesaving for people with obesity and diabetes and improving access to care. Stay tuned for our next series on pediatric health. 
 
Additional obesity-related resources can be found on our Focus on Obesity page: https://bit.ly/3yV6Ihc 

You may also like